Medtronic plc (MDT)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
On balance, Medtronic looks healthy: the strengths outweigh the weak spots.
- What's working
- Sales and profits grew faster over the past year than at most other healthcare companies.
- Worth watching
- No major weak spots stand out in the data right now.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio…
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 95,000
- Headquarters
- Galway, Ireland
Similar stocks
What’s behind the score
Valuation
P/E 23.3 — lower than 71% of Healthcare peers
P/B 2.4 — lower than 71% of Healthcare peers
P/S 3.2 — lower than 60% of Healthcare peers
EV/EBITDA 13.6 — lower than 57% of Healthcare peers
EV/Revenue 3.8 — lower than 60% of Healthcare peers
PEG 1.7 — lower than 44% of Healthcare peers
FCF yield 4.5% — higher than 69% of Healthcare peers
Profitability & quality
Gross margin 65.3% — higher than 53% of Healthcare peers
Operating margin 19.3% — higher than 43% of Healthcare peers
Net margin 13.9% — higher than 53% of Healthcare peers
ROE 10.6% — higher than 48% of Healthcare peers
ROA 5.1% — higher than 31% of Healthcare peers
Free cash flow is 103% of reported net income
Financial health
Debt/equity 0.6 — lower than 67% of Healthcare peers
Current ratio 2.07 — higher than 79% of Healthcare peers
Quick ratio 1.29 — higher than 72% of Healthcare peers
Cash/debt 0.31 — higher than 69% of Healthcare peers
Debt/EBITDA 2.70 — lower than 34% of Healthcare peers
Growth
Revenue growth 13.7% YoY — higher than 87% of Healthcare peers
Earnings growth 40.7% YoY — higher than 69% of Healthcare peers
Ownership & investor activity
Payout ratio 70.0% — atypical vs Healthcare peers
Net insider buying, +7.8% of insider shares
Institutions net sold, -14.2% of shares held
Insiders hold 0.3% of shares outstanding
3.1% of float sold short
Momentum
Above its 50- & 200-day averages
65% of the way from its 52-week low to high